Literature DB >> 10858531

Identification of domains within the epsilon-subunit of the translation initiation factor eIF2B that are necessary for guanine nucleotide exchange activity and eIF2B holoprotein formation.

T G Anthony1, J R Fabian, S R Kimball, L S Jefferson.   

Abstract

Eukaryotic translation initiation factor, eIF2B, is a guanine nucleotide exchange factor (GEF) composed of five dissimilar subunits. eIF2B is important for regenerating GTP-bound eIF2 during the initiation process. This event is obligatory for eIF2 to bind initiator methionyl-tRNA, forming the ternary initiation complex. In the current investigation, deletion mutants of the catalytic subunit, eIF2B epsilon, were constructed to identify regions that are necessary for eIF2B catalytic activity and formation of the holoprotein. We used the baculovirus expression system to coexpress wild-type and truncated forms of the epsilon-subunit of mammalian eIF2B (eIF2B epsilon) with the other four subunits (alpha, beta, gamma, delta) of the protein in Sf9 cells. Removal of either the N- or the C-terminal conserved domains of eIF2B epsilon resulted in a significant loss of GEF activity and reduced or abolished interaction with the alpha-, gamma- and delta-subunits of eIF2B. Removal of the C-terminal 552 amino acids of eIF2B epsilon markedly reduced its interaction with the beta-subunit of eIF2 whereas loss of the N-terminal 431 amino acids did not. The results suggest that intact eIF2B epsilon is required for full catalytic activity and formation of the eIF2B holoprotein. In contrast, the C-terminal domain of eIF2B epsilon is sufficient alone for binding the beta-subunit of its substrate, eIF2, in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858531     DOI: 10.1016/s0167-4781(00)00062-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Inhibition of glycogen synthase kinase 3[beta] activity with lithium in vitro attenuates sepsis-induced changes in muscle protein turnover.

Authors:  Stephen Bertsch; Charles H Lang; Thomas C Vary
Journal:  Shock       Date:  2011-03       Impact factor: 3.454

2.  Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts.

Authors:  Darren J Perkins; Glen N Barber
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

3.  Ectopic expression of eIF2Bepsilon in rat skeletal muscle rescues the sepsis-induced reduction in guanine nucleotide exchange activity and protein synthesis.

Authors:  Alexander P Tuckow; Thomas C Vary; Scot R Kimball; Leonard S Jefferson
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-05-18       Impact factor: 4.310

4.  The beta/Gcd7 subunit of eukaryotic translation initiation factor 2B (eIF2B), a guanine nucleotide exchange factor, is crucial for binding eIF2 in vivo.

Authors:  Kamal Dev; Hongfang Qiu; Jinsheng Dong; Fan Zhang; Dominik Barthlme; Alan G Hinnebusch
Journal:  Mol Cell Biol       Date:  2010-08-30       Impact factor: 4.272

5.  Characterization of the minimal catalytic domain within eIF2B: the guanine-nucleotide exchange factor for translation initiation.

Authors:  Edith Gomez; Sarah S Mohammad; Graham D Pavitt
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

6.  Identification of residues that underpin interactions within the eukaryotic initiation factor (eIF2) 2B complex.

Authors:  Xuemin Wang; Noel C Wortham; Rui Liu; Christopher G Proud
Journal:  J Biol Chem       Date:  2012-01-11       Impact factor: 5.157

7.  Identification of intersubunit domain interactions within eukaryotic initiation factor (eIF) 2B, the nucleotide exchange factor for translation initiation.

Authors:  Peter J Reid; Sarah S Mohammad-Qureshi; Graham D Pavitt
Journal:  J Biol Chem       Date:  2012-01-11       Impact factor: 5.157

Review 8.  The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases.

Authors:  Cristian A Droppelmann; Danae Campos-Melo; Kathryn Volkening; Michael J Strong
Journal:  Front Cell Neurosci       Date:  2014-09-10       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.